The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 01, 2022

Filed:

Aug. 26, 2020
Applicant:

Amgen Inc., Thousand Oaks, CA (US);

Inventors:

George W. Muller, Rancho Sante Fe, CA (US);

Peter H. Schafer, Belle Mead, NJ (US);

Hon-Wah Man, Princeton, NJ (US);

Chuansheng Ge, Belle Mead, NJ (US);

Assignee:

AMGEN INC., Thousand Oaks, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07C 317/28 (2006.01); A61K 31/4035 (2006.01); C07D 209/48 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4035 (2013.01); A61K 45/06 (2013.01); C07C 317/28 (2013.01); C07D 209/48 (2013.01); C07B 2200/07 (2013.01); Y02A 50/30 (2018.01);
Abstract

Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (−) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-α or the inhibition of PDE4.


Find Patent Forward Citations

Loading…